Stocktoria
CURIS INC CRIS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-08-01
CURIS INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -60.5% | -408.3% | -482.2% | -521.7% | -395.0% |
| Net margin | -80.3% | -397.8% | -473.0% | -557.7% | -426.7% |
| FCF margin | — | — | -383.5% | -538.8% | -353.3% |
| Return on assets | -38.0% | -105.1% | -61.4% | -52.1% | -28.0% |
| Return on equity | -138.8% | 723.4% | -241.0% | -121.7% | -50.1% |
| Current ratio | 0.49 | 1.39 | 2.77 | 9.20 | 9.11 |
| Revenue growth | -13.4% | 8.8% | -1.4% | -4.6% | -1.7% |
Source: SEC EDGAR filings · CIK 0001108205 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.